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Aberrations in the G1/S transition of the cell cycle have been observed in many malignancies and seem to be critical in the
transformation process. Few studies have delineated the presence of G1/S regulatory defects and their clinical relevance in renal cell
carcinoma (RCC). Therefore, we have examined the protein contents of cyclin D1, D3, E, and p27 in 218 RCCs, using tissue
microarray and immunohistochemistry. The results from a subset of tumours were confirmed by Western blotting and
immunohistochemical staining of regular tissue sections. Interestingly, low protein contents of cyclin D1 and p27 were associated with
high nuclear grade, large tumour size, and poor prognosis for patients with conventional tumours. We further observed substantial
differences in the pattern of G1/S regulatory defects between the different RCC subtypes. The majority of both conventional and
papillary cases expressed p27; however, chromophobe tumours generally lacked p27 staining. In addition, conventional RCCs often
expressed high cyclin D1 protein levels, while papillary RCCs exhibited high cyclin E. In summary, we have shown that G1/S
regulatory defects are present in RCC and are associated with clinico-pathological parameters. The pattern of cell cycle regulatory
defects also differed between RCC subtypes.
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The G1/S transition is a crucial checkpoint in the control of
proliferation during cell cycle progression. With an intact G1/S
checkpoint, cells with minor DNA damages are stopped and
aberrations are repaired before S-phase entrance. Cells with
widespread alterations undergo apoptosis (Harbour and Dean,
2000). Different defects affecting the regulation of the G1/S
transition have been detected in various malignancies (Bartkova
et al, 1996; Gillet et al, 1996; Hommura et al, 2000; Kawauchi et al,
2001). This suggests that cell cycle aberrations probably represent
one of a limited number of key events in the transformation
process (Hahn et al, 1999). Therefore, characterisation of G1/S
regulatory proteins and the delineation of different aberrations in
tumours are important for the understanding of tumour develop-
ment and progression.
Several proteins control the G1/S transition, but the activators
cyclin D and E are rate limiting for S-phase entrance. The cyclins
belong to a large, evolutionary conserved protein family and are
expressed at specific cell cycle phases. The cyclin-dependent
kinases (cdks) are activated by the cyclins and inhibited by cdk
inhibitors such as p16, p21, and p27 (Lees, 1995; Reed, 1997).
Cyclin D-activated kinases (CDK4/6) initiate a cascade of events
starting with site-specific phosphorylation of pRb, which generates
a partial release of the transcription factor E2F. This results in a
subsequent activation of E2F-responsive genes such as cyclin E,
which enables the formation of active cyclin E/cdk2 complex and
an extensive phosphorylation of pRb and S-phase entrance. During
the activation of the cyclin E/cdk2 complex, the inhibitor p27
releases from the complex and is sequestered by cyclin D1 (Sherr,
2000).
So far, only a few studies have evaluated cell cycle alterations in
human renal cell carcinoma (RCC). Earlier, we have shown that the
cyclin D1 and E proteins were highly expressed in a large fraction
of RCCs, and high cyclin D3 levels were observed in 16% of the
tumours. For most RCCs, the p27 protein content seemed to be
unaltered, but in a small fraction of the tumours p27 protein was
low or undetectable. Low p27 was associated with poor prognosis
and large tumour size in conventional RCCs (Hedberg et al, 1999,
2002a, b). We have also shown that low cyclin D1 protein content
was associated with a shorter survival time (Hedberg et al, 1999).
In contrast, Aaltomaa et al (1999) found that the cyclin D1 or p21
protein contents had no prognostic value in RCC. Molecular
alterations of the Rb gene and aberrant pRb expression seem to be
infrequent in RCC (Presti et al, 1996; Lai et al, 1997). This suggests
that mainly the regulating molecules in the G1/S transition are
deregulated in RCC, whereas the substrate pRb is unaffected.
Tissue microarray (TMA) is a new method that enables analysis
of a large number of samples using various methods. Selected areas
of archival paraffin-embedded tissues are biopsied and mounted in
a TMA block, which permits multiple analysis of a large collection
of samples and use of a limited amount of tissue. In addition, this
method creates a uniform platform to stain and evaluate protein,
RNA, and DNA using immunohistochemistry and in situ
hybridisation methods (Kononen et al, 1998; Moch et al, 1999;
Kallioniemi et al, 2001).
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involved in the G1/S transition in a large amount of RCC, using the
TMA technique and immunohistochemistry. In order to validate
the results obtained by the TMA technique, the data were
compared with regular immunohistochemistry sections and
Western blotting using protein extracts prepared from a subset
of the tumours.
MATERIAL AND METHODS
Patient data
The TMA blocks contained 238 RCCs, all of which were
represented by two tissue cores. Eight tumours were excluded
because of necrosis, and 12 tumours were excluded because of
disagreement between the two tissue cores considering staining
(n¼7) or morphology (n¼5). In total, 218 tumours were included
and characterised in this study. There were 127 men and 91 women
and the mean age of the patients was 65.1 years (range 25–87
years). The samples were collected between 1982 and 1997 at the
University Hospital in Umea ˚, Sweden. All tumour samples were
obtained after permission from the patients and during the last 6
years with informed and signed consent. The patients were
followed according to a scheduled followup programme including
clinical and radiological examinations. At the last followup, 63
patients were alive, 105 patients had died of the disease, and 50
patients were deceased because of other events. The median
followup time for patients alive was 97 months (range 38–209
months). Clinical staging was performed according to the 1997
TNM classification system (Sobin and Wittekind, 1997), and
nuclear grading was performed according to Skinner et al (1971).
The tumours were also classified according to the Heidelberg
classification system (Kovacs et al, 1997). There were 175
conventional, 29 papillary, and 14 chromophobe RCCs. Tumour
size was measured on the surgical specimens and/or on
computerised tomographies.
Construction of TMA blocks
One pathologist (GL) screened sections from a large amount of
RCC material and selected areas of the paraffin-embedded tissue
specimens that contained representative tumour cells. If hetero-
geneity (regarding differentiation) was observed, then the parts
with the lowest differentiation grade were selected. Two tissue
cores (0.6mm in diameter) were taken from each tumour sample
and placed in a new recipient paraffin block using a commercially
available microarray instrument (Beecher Instruments, USA). Each
TMA block included 98 tissue cores and the total RCC material was
mounted in six blocks.
Antibodies and staining procedures
Paraffin sections (4mm) from the TMA blocks were deparaffinised
and microwave treated according to standard procedures before
being processed in an automatic immunohistochemical staining
machine (Ventana 320-202, Ventana Inc., Tucson). An AEC
detection kit was used. Cyclin D1 was detected by monoclonal
antibody M7155 (DAKO, Sweden), diluted 1/20, and cyclin D3 by
the 14781C antibody (Becton Dickinson, Belgium), diluted 1/50.
Antigen retrieval was performed in 0.01 M citrate buffer (pH 6.0)
for 15min. Cyclin E was detected by HE-12 monoclonal antibodies
(Santa Cruz, CA, USA), diluted 1/50 after antigen retrieval in EDTA
(pH 8.0), and p27 was detected by Kip1 antibody (Transductional
Laboratories, KY, USA), diluted 1/200, after antigen retrieval in a
citrate buffer (pH 6.0). The Ab-3 antibody (Neomarkers, England)
was used for the VEGF staining (1/50) after antigen retrieval in
EDTA buffer. Stainings were performed on consecutive sections.
Evaluation of the immunohistochemical staining
The expression of cyclin D1, D3, E, and p27 was evaluated in
four groups (1–4). Tumours that lacked nuclear staining were
defined as group 1 and tumours with less than five positive
cells per tissue core were defined as group 2. These two groups
were defined as tumours with low protein content. The staining
pattern of the various proteins in the RCCs with high protein
levels varied, and therefore separate definitions for groups 3
and 4 were used. For cyclin D1, tumours with more than five
positive cells per tissue core showed nuclear staining in most
cells, but with a clear variation in staining intensity. Group 3
was defined as more than five positive cells, but with low
cyclin D1 staining intensity, whereas tumours with high intensity
were defined as group 4. For cyclin D3, tumours with more
than five positive cells per tissue core but less than 80% positive
cells were defined as group 3. Group 4 had more than 80%
cyclin D3-positive tumour cells. For cyclin E, group 3 was defined
as tumours with more than five positive cells per tissue core
and less than 50% positive tumour cells, and group 4 was
defined as tumours with more than 50% positive cells. For p27,
tumours with more than five positive cells per tissue core and a
variable staining intensity in the separate cells were defined as
group 3 tumours, and those with a high-intensity staining in all
tumour cells were defined as group 4. Sixteen of the 218 RCCs
lacked nuclear staining of cyclin D1, D3, E, and p27 in the tumour
cells. To evaluate whether a fixation error had produced false-
negative results, VEGF staining was used as a positive control.
Fifteen of the 16 tumours showed a positive VEGF staining and
most tumours had positive p27 staining in normal cells and/or
cytoplasmic cyclin staining. Therefore, the 16 tumours that lacked
nuclear staining of cyclin D1, D3, E, and p27 were included in the
analysis.
Western blotting
Preparation of protein extracts from fresh frozen tissues and
electrophoresis were performed as described earlier (Hedberg et al,
1999, 2002a, b). Briefly, protein extract from each sample and a
positive control was separated on SDS–polyacrylamide gels and
the proteins were transferred to nitrocellulose membranes
(Hybond-N, Amersham Int., England). The membranes were
probed with anti-cyclin D1 DCS-6 antibodies (1:500, a kind gift
from Dr Jiri Bartek, Copenhagen, Denmark), anti-HE12 antibodies
(1:1500, Santa Cruz, CA, USA), anti-cyclin D3 G107-565
antibodies (1:250, Pharmingen, San Diego, CA, USA), and actin
antibodies (1:2000, Boehringer-Mannheim GmbH, Germany).
Ponceau Red and actin were used as loading and degradation
controls.
Several cyclin E reactive bands were observed in the Western
blots, as also described in detail earlier (Keyomarsi et al, 1995).
Previous studies have shown good agreement between immuno-
histochemistry and Western blot analyses using HE12, cyclin E
antibodies (Nielsen et al, 1998) validating the specificity of the
antibody.
Statistical analysis
When both parameters contained nominal data, Fisher’s exact test
was performed. The Kruskal–Wallis test was used to compare the
distributions of a variable for groups. For survival analysis, log-
rank tests and Kaplan–Meier curves were used, and for multi-
variate analysis, the Cox-regression model was used. If no event
occurred, the patient was censored at the time of the last clinical
followup or death from other causes. A P-value less than 0.05 was
considered statistically significant. Statistical analysis was per-
formed using the SPSS 9.0 software.
Tissue microarray, cell cycle proteins, and RCC
Y Hedberg et al
1418
British Journal of Cancer (2003) 88(9), 1417–1423 & 2003 Cancer Research UK
M
o
l
e
c
u
l
a
r
a
n
d
C
e
l
l
u
l
a
r
P
a
t
h
o
l
o
g
yRESULTS
Protein expression during G1/S transition in RCC
Examples of immunohistochemistry staining of cyclin D1, D3, E,
and p27 are shown in Figure 1 and data are summarised in Table 1.
The formalin-fixed tumour blocks had been stored for 2–18 years
before the TMAs were constructed. In order to test if the results
differed depending on the storage time, the proportion of
positively stained tumour cells was plotted for each year (data
not shown). The results were uniform during the study period,
indicating that the studied proteins were stable at least up to 18
years.
Evaluation of the TMA technique
The relative protein concentrations of cyclin D1, D3, and E have
been previously analysed by Western blotting in 68 of the tumours
included in the TMA (Hedberg et al, 1999, 2002a, b). Representa-
tive Western blots are shown in Figure 2. As illustrated in
Figure 3A, the cyclin D1 expression evaluated in the TMA
correlated with the Western data (Po0.001). Similar correlation
was obtained for the cyclin D3 staining (Figure 3A). The few cyclin
D3 high RCCs, according to Western blot analysis, had high levels
of cyclin D3 (scored as group 4) evaluated by the TMA (Po0.001).
For cyclin E, no association was observed between the TMA
evaluation and Western blot results (P¼0.839, Figure 3A).
Nevertheless, the TMA results correlated to the fraction of cyclin
E positive cells evaluated by immunohistochemistry using regular
sections (Po0.001, data not shown). The expression of p27 has
been evaluated by immunohistochemistry using both the TMA
technique and regular sections (Hedberg et al, 2002b) (the two
methods corresponded significantly (P¼0.009)), validating the
results obtained from the TMA (Figure 3B).
Conventional RCC
In conventional RCC, low cyclin D1 and p27 protein levels were
associated with high nuclear grade and large tumour size (Table 2).
Expression of cyclin D1 and p27 were not linked to gender, age, or
stage (data not shown). The protein contents of cyclin D3 and E
were not associated with nuclear grade, tumour size, gender, age,
stage, or survival (data not shown). Patients with cyclin D1
low
tumours had an impaired survival compared with those
having cyclin D1
high tumours (P¼0.019, Figure 4A). In addition,
low levels of p27 were associated with a poor prognosis
(P¼0.037, Figure 4B). Multivariate analysis was performed in
Cyclin D1
p27
Cyclin E
Cyclin D3
Low High
Figure 1 Illustration of cyclin D1, D3, E, and p27 immunohistochemistry
staining of RCC using TMA technique. The left column illustrates a low
protein expression, and the right column shows tumours with high content
of the cell-cycle-regulating proteins.
Table 1 Protein expression of cyclin D1, D3, E, and p27 evaluated by
TMA, graded into four groups from negative (1) to positive (4)
Conventional Papillary Chromophobe
Cyclin D1
1 Low 64 47% 21 90% 11 79%
21 8 5 0
3 High 30 53% 2 10% 1 21%
46 2 1 2
Cyclin D3
1 Low 108 83% 21 90% 10 86%
23 3 5 2
3 High 17 17% 1 10% 1 14%
41 2 2 1
Cyclin E
1 Low 72 68% 9 67% 5 46%
24 7 9 1
3 High 41 32% 7 33% 2 54%
41 4 2 5
p27
1 Low 16 20% 6 34% 8 64%
21 9 4 1
3 High 115 80% 18 66% 5 36%
42 1 1 0
Numbers of cases in each group are noted
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Figure 2 Illustration of Western blot analysis of cyclin D1, D3, E, and
actin in RCC. Actin was used as a loading control. The first lane, marked
9003 N, represents corresponding kidney cortex from patient 9003,
whereas the tumour sample was loaded in lane 2. The other six lanes
contain tumour samples to illustrate the variation in protein contents
between the tumours.
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and TNM as parameters (Table 3). Independent significant factors
were nuclear grade, TNM, and p27.
In the G1/S regulatory defects in conventional RCCs, we
observed that tumours with high protein contents of cyclin D1,
D3, or E also had high levels of p27 (Table 4). Furthermore, cyclin
E was significantly associated with cyclin D1 (P¼0.001) and D3
(Po0.001), but there was no association between cyclin D1 and D3
protein levels. Figure 5A summarises the data from the analysed
cell cycle regulatory proteins. The majority of the tumours that
lacked p27 also lacked staining of all the three cyclins. Although
these negative tumours were positive for VEGF, a protein served as
a positive control for unspecific protein degradation (data not
shown). Among the p27-positive tumours, cyclin D1 was the most
frequently expressed cyclin either alone or in combination with
cyclin E and/or cyclin D3.
Papillary RCC
In papillary RCC, there was no association between cell cycle
proteins and clinico-pathological parameters (data not shown).
Furthermore, there was no correlation between the expressions of
the different cell cycle proteins (Table 4). When the distribution of
the cell cycle protein expression levels was analysed, two dominant
expression patterns were observed (Figure 5B). The most common
pattern (52% of the papillary RCC) showed low levels of all the
three cyclins. The other main pattern, including 30% of the
tumours, contained high p27 and cyclin E protein levels, but low
levels, of cyclin D1 and D3. It should be noted that papillary RCC
seldom expressed cyclin D1 or D3.
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Figure 3 Comparison between TMA-based immunohistochemistry analysis of cyclin D1, D3, E, and p27 (1–4) with (A) Western-blot-based analysis
(cyclin D1, D3, and E) or (B) immunohistochemistry of regular sections (p27).
Table 2 Association between cyclin D1/p27 expression and nuclear
grade/tumour size in conventional RCC
Nuclear grade Tumour size
1+2 3 4 P-value
Mean
(cm)
Mean
rank P-value
Cyclin D1
Low 7 40 34 o0.001 8.7 102.1 o0.000
High 25 51 15 6.9 73.7
p27
Low 2 18 15 0.007 8.7 101.4 0.026
High 31 69 33 7.4 80.7
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In the rather few chromophobe RCCs (n¼13), cyclin D1, D3, E,
and p27 protein contents were not associated with any clinico-
pathological parameters (data not shown). There was an associa-
tion between p27 and cyclin D1 and E proteins (P¼0.027,
P¼0.021, respectively) but not between p27 and cyclin D3
(P¼0.110, Table 4). In addition, there was no correlation between
the levels of cyclin D1, D3, and E, respectively. Chromophobe RCC
showed different cell cycle regulatory protein expression patterns
compared with conventional and papillary RCC (Figure 5C). The
largest group of tumours (46%) had low levels of the three cyclins
as well as p27. In the other tumours, cyclin E was highly expressed
either alone or in combination with high cyclin D1 and/or D3
levels.
DISCUSSION
In this study, the protein contents of cyclin D1, D3, E, and the cdk-
inhibitor p27 were analysed in a large amount of RCC using the
TMA technique and immunohistochemistry. Tissue microarray is
a powerful method that enables analysis of large tumour materials
treated in an identical manner, which reduces the slide-to-slide
variability and the amount of reagents required. One disadvantage
with this method is that rather small tissue areas are evaluated.
This limits the amount of normal and tumour cells, which can be a
problem when analysing different parameters in tumours with
marked heterogeneity.
RCC is a disease with known heterogeneity regarding morphol-
ogy and DNA ploidy (Ljungberg et al, 1996). However, it is still
unclear whether the heterogeneity concerns cell cycle regulatory
proteins. In this study, we found an agreement in staining and
morphology between the two corresponding tissue cores in 95% of
the tumours, suggesting a minor variation between the two
biopsied areas. Our data correspond to the results obtained in a
study on breast cancer, showing that the analysis of two tissue
cores was comparable to the analysis of a whole tissue section in
more than 95% of the cases (Camp et al, 2000).
By comparing the TMA results with the protein expression, we
found that regular immunohistochemistry and Western blot
validated the TMA technique. For p27, the TMA data correlated
well to the regular immunohistochemical analysis and the staining
of cyclin D1 and D3 on the TMA correlated to the corresponding
Western blot analysis. In contrast, the cyclin E expression detected
on the TMA disagreed with the Western blot analysis; however, the
TMA results of cyclin E corresponded significantly to immuno-
histochemical stainings of regular tissue sections. These data
suggest that the TMA technique was not the limiting factor. One
reason for the disagreement might be the existence of isoforms of
cyclin E, which potentially could affect the cyclin E evaluation.
Several bands with different molecular weights were detected in the
Western blot analysis (Hedberg et al, 2002b), and all bands were
considered to represent the cyclin E protein (Keyomarsi et al,
1995). It is also possible that the antibody will not recognise all
isoforms, due to the fixation procedure or due to other influences
on the protein structure during the tissue processing.
The tumour specimens in the present study have been stored up
to 18 years, but there was no indication that the staining efficiency
was changed during the storage time. Our results agree with other
studies on oestrogen receptor, progesterone receptor, and Her2/
neu on breast cancer, which report that most paraffin-embedded
materials up to an age of at least 68 years are still useful for
immunohistochemical analysis (Camp et al, 2000). On the
contrary, Larsson et al (1996) reported that tumours archived
for many years lost the antigenicity for PCNA staining, suggesting
that various antigens are affected differently by storage time.
Nevertheless, the quality of the archived samples is an important
aspect when designing TMAs. Our results suggest that up to 18-
year old tumour samples can be used for immunohistochemical
analysis of cyclin D1, D3, E, and p27.
We showed that the expression pattern of the evaluated cell
cycle proteins varied between the different RCC types. These
results agree with the finding that specific genetic aberrations
characterise the different subtypes of RCC (Kovacs et al, 1997),
although none of the genes for cyclin D1 (11q3), cyclin D3 (6p21),
or cyclin E (19q12-13) are mapped to the chromosomes with
characteristic abnormalities in RCC (Inaba et al, 1992; Demetrick
et al, 1995; Kovacs et al, 1997).
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Figure 4 Kaplan–Meier survival curves for patients with conventional
RCC: (A) cyclin D1 (low vs high levels); (B) p27 (low vs high levels).
Table 3 Multivariate Cox analysis of 155 conventional RCCs (77 events)
95% CI
Variable Exp (B) Lower Upper P-value
Cyclin D1 (low vs high) 0.899 0.500 1.618 0.723
Cyclin D3 (low vs high) 1.079 0.583 1.996 0.808
Cyclin E (low vs high) 1.247 0.742 2.094 0.405
p27 (low vs high) 0.386 0.194 0.766 0.007
Nuclear grade (1+2 vs 3+4) 6.053 1.879 19.493 0.003
TNM (I–III vs IV) 9.331 5.515 15.786 o0.001
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p27 correlated to poor prognosis in conventional RCC using
univariate analysis, and that p27 remained significantly associated
to survival in the multivariate analyses. The association between
low cyclin D1 and poor prognosis in the univariate analysis agrees
with the data reported for breast cancer (Gillet et al, 1996; Nielsen
et al, 1997; Hwang et al, 2002; McKay et al, 2002), although an
association between high cyclin D1 and poor prognosis has been
reported in many malignancies (A ˚kervall et al, 1997; Gansauge
et al, 1997).
In conclusion, we have analysed various cell cycle regulatory
proteins in RCC and showed that the TMA technique is a reliable
and useful technique for analysis of several proteins even in a
heterogeneous tumour such as RCC. Aberrations in cyclin D1 and
p27 were further associated with nuclear grade, tumour size, and
patient survival. Interestingly, specific patterns of alterations in
cell cycle regulators seemed to be characteristic for the different
RCC types.
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Table 4 Illustration of the association between the protein contents of cyclin D1, D3, E, and p27 in
conventional, papillary, and chromophobe RCCs
Cyclin D1 Cyclin D3 Cyclin E
Low High P-value Low High P-value Low High P-value
Conventional
Cyclin D3
Low 69 71 0.310
High 11 18
Cyclin E
Low 66 52 0.001 106 10 o0.001
High 16 39 34 19
p27
Low 34 1 o0.001 33 1 o0.010 30 5 0.009
High 44 90 103 28 84 50
Papillary
Cyclin D3
Low 24 2 0.288
High 2 1
Cyclin E
Low 15 3 0.529 16 2 1.000
High 9 0 8 1
p27
Low 9 1 1.000 10 0 0.532 6 2 0.676
High 17 2 16 3 12 7
Chromophobe
Cyclin D3
Low 10 2 0.396
High 1 1
Cyclin E
Low 6 0 0.192 6 0 0.462
High 4 3 5 2
p27
Low 9 0 0.027 9 0 0.110 6 2 0.021
H i g h 23 3 2 05
0
10
20
30
40
50
60
0
10
20
30
40
50
60
0
10
20
30
40
50
60
C
h
r
o
m
o
p
h
o
b
e
 
(
%
)
 
P
a
p
i
l
l
a
r
y
 
(
%
)
C
o
n
v
e
n
t
i
o
n
a
l
 
(
%
)
++
− +
+
−
+
+
+
+
−
−
−
+
−
+
−
+
−
−
−
−
− +
cyclin D1
cyclin D3
cyclin E
p27 −
p27 +
A
B
C
Figure 5 An illustration of the combinations of alterations in cell cycle
regulatory proteins in (A) 163 conventional, (B) 27 papillary, and (C)1 3
chromophobe RCC. The light grey bars represent tumours having low p27
levels, while the dark grey bars represent tumours with high p27 levels. The
presence of low and high cyclin expression are indicated as   and þ.
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